Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-03-17 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
山西惠瑞药业有限责任公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It includes detailed financial statements such as balance sheets, profit and loss statements, cash flow statements, changes in equity, and notes to the financial statements. The document contains an auditor's opinion, responsibilities of management and auditors, and is signed by a certified public accounting firm. The financial data covers the fiscal year ending December 31, 2013, and the period up to February 28, 2014. The length of the document is substantial (15,000 characters), indicating it is the full audit report rather than a brief announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR).
2014-03-17 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2013 by 普洛药业股份有限公司. It discusses the company's internal control systems, governance structure, risk management, and compliance with relevant laws and regulations. The content is detailed and comprehensive, covering internal control activities, evaluation, and independent directors' opinions. It does not present financial statements or quarterly/annual financial results but focuses on internal control evaluation and governance. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations, excluding full annual reports. The document length (4725 characters) is sufficient to be the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2013
2014-03-17 Chinese
2013年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a non-public share issuance by 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.) for the year 2013. It includes specifics about the amount raised, the management of the funds, compliance with regulatory approvals, and the actual usage of the funds, including replacement of prior bank loans and project investments. The document references regulatory approvals from the China Securities Regulatory Commission and includes an auditor's verification report number. The content focuses on the management and actual use of capital raised, which aligns with a Capital/Financing Update. The document length is 3133 characters, which is relatively short but contains substantive financial and usage details, not merely an announcement or certification. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not an Annual Report or Interim Report as it does not cover full financial performance but specifically addresses fundraising and capital usage. Hence, the best fitting category is Capital/Financing Update (CAP).
2014-03-17 Chinese
拟股权收购所涉及山西惠瑞药业有限责任公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is an asset valuation report related to a proposed equity acquisition by 普洛药业股份有限公司 of 山西惠瑞药业有限责任公司. It contains detailed asset evaluation, valuation methods, legal and financial background, and audit references. The document is lengthy (15,000 characters) and includes substantive financial data, asset and liability details, valuation conclusions, and audit opinions. It is not a brief announcement or a certification letter but a full asset evaluation report prepared by an independent appraisal firm. The content aligns with an Audit Report / Information (AR) category, as it is a standalone asset valuation report used for acquisition purposes, not a full annual or interim financial report. Therefore, the appropriate classification is AR with high confidence.
2014-03-17 Chinese
第五届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the 5th Board of Directors of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.) held on March 17, 2014. It includes approvals of the 2013 Annual Report, Board and General Manager work reports, financial reports, profit distribution plans, and other corporate governance matters. It also contains detailed information about the nomination of directors and independent directors, amendments to the company bylaws (articles of association), and other board-level decisions. The document is not the annual report itself but a formal announcement of board meeting resolutions that will be submitted to the shareholders' meeting for approval. The presence of voting results for each agenda item and the detailed description of board decisions indicate this is a Board/Management Information filing. It is not a proxy statement or AGM materials, nor is it a full annual report or audit report. Therefore, the appropriate classification is MANG (Board/Management Information). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive board meeting resolution announcement.
2014-03-17 Chinese
非公开发行股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票预案（修订稿）" which translates to "Non-public Stock Issuance Proposal (Revised)". It details a plan for a non-public issuance of A shares by the company 普洛药业股份有限公司. The content includes detailed information about the issuance plan, background, purpose, pricing, number of shares, use of proceeds, related party transactions, and approvals required. It also includes financial data and analysis related to the issuance and the involved parties. The document is lengthy (15,000 characters) and contains substantive financial and business information about the capital raising activity. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a full annual or interim report, nor a regulatory filing or certification. Therefore, the correct classification is CAP with high confidence.
2014-03-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.